{"id":"https://openalex.org/W2021513482","doi":"https://doi.org/10.1038/clpt.2014.158","title":"Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid\u2013Mediated Troglitazone Hepatotoxicity","display_name":"Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid\u2013Mediated Troglitazone Hepatotoxicity","alternate_titles":[],"publication_year":2014,"publication_date":"2014-07-28","ids":{"openalex":"https://openalex.org/W2021513482","doi":"https://doi.org/10.1038/clpt.2014.158","mag":"2021513482","pmid":"https://pubmed.ncbi.nlm.nih.gov/25068506","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4480860"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.2014.158","doi":"https://doi.org/10.1038/clpt.2014.158","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2014.158","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2021513482"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4480860/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"K Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K Yang","raw_affiliation_strings":["Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110303613","display_name":"Jeffrey L. Woodhead","orcid":"https://orcid.org/0009-0001-3326-1210","observed_orcids":["https://orcid.org/0009-0001-3326-1210"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210093870","display_name":"The Hamner Institutes for Health Sciences","ror":"https://ror.org/00jjvav84","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210093870"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J L Woodhead","raw_affiliation_strings":["The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210093870"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062878299","display_name":"Paul Brent Watkins","orcid":"https://orcid.org/0000-0001-9541-8917","observed_orcids":["https://orcid.org/0000-0001-9541-8917","https://orcid.org/0009-0008-3343-4418"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210093870","display_name":"The Hamner Institutes for Health Sciences","ror":"https://ror.org/00jjvav84","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210093870"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P B Watkins","raw_affiliation_strings":["1] Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [2] The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA","Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1] Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [2] The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210093870"]},{"raw_affiliation_string":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":null,"display_name":"B A Howell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210093870","display_name":"The Hamner Institutes for Health Sciences","ror":"https://ror.org/00jjvav84","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210093870"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B A Howell","raw_affiliation_strings":["The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Hamner-UNC Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210093870"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056589677","display_name":"Kim L. R. Brouwer","orcid":"https://orcid.org/0000-0003-1945-4929","observed_orcids":["https://orcid.org/0000-0003-1945-4929"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"K L R Brouwer","raw_affiliation_strings":["1] Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [2] Current address: UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1] Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [2] Current address: UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5056589677"],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":9.4025,"has_fulltext":true,"cited_by_count":100,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.9924843,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"96","issue":"5","first_page":"589","last_page":"598"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10966","display_name":"Liver physiology and pathology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/troglitazone","display_name":"troglitazone","score":0.9890000224113464},{"id":"https://openalex.org/keywords/drug-induced-liver-injury","display_name":"drug-induced liver injury","score":0.8500000238418579},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.9409999847412109},{"id":"https://openalex.org/keywords/bile-acid-homeostasis","display_name":"bile acid homeostasis","score":0.8799999952316284},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9760000109672546},{"id":"https://openalex.org/keywords/species-differences","display_name":"species differences","score":0.8029999732971191},{"id":"https://openalex.org/keywords/alanine-aminotransferase","display_name":"alanine aminotransferase","score":0.796999990940094},{"id":"https://openalex.org/keywords/bilirubin","display_name":"bilirubin","score":0.9729999899864197},{"id":"https://openalex.org/keywords/drug-safety-prediction","display_name":"drug safety prediction","score":0.5849999785423279},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.8560000061988831}],"concepts":[{"id":"https://openalex.org/C2778150266","wikidata":"https://www.wikidata.org/wiki/Q7844989","display_name":"Troglitazone","level":4,"score":0.7626760005950928},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6434487700462341},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.5317842960357666},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5130876302719116},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5109654664993286},{"id":"https://openalex.org/C2779399885","wikidata":"https://www.wikidata.org/wiki/Q413288","display_name":"Bile acid","level":2,"score":0.5085021257400513},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5068634152412415},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5014817714691162},{"id":"https://openalex.org/C2778606649","wikidata":"https://www.wikidata.org/wiki/Q305481","display_name":"Alanine transaminase","level":2,"score":0.4743082523345947},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.47205406427383423},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4225006699562073},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3363193869590759},{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.13596132397651672},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07392072677612305},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074020","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 11","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077288","descriptor_name":"Troglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000410","descriptor_name":"Alanine Transaminase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001647","descriptor_name":"Bile Acids and Salts","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D002839","descriptor_name":"Chromans","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012044","descriptor_name":"Regression Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013045","descriptor_name":"Species Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018528","descriptor_name":"ATP-Binding Cassette Transporters","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056486","descriptor_name":"Chemical and Drug Induced Liver Injury","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1038/clpt.2014.158","doi":"https://doi.org/10.1038/clpt.2014.158","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2014.158","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:25068506","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25068506","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4480860","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4480860/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Pharmacol Ther","raw_type":"Text"},{"id":"pmh:cdr.lib.unc.edu:73666b64j","doi":null,"is_oa":true,"landing_page_url":"https://doi.org/10.17615/w6gf-6j96","pdf_url":"https://cdr.lib.unc.edu/downloads/1z40m103h","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacology & Therapeutics (Nature), 96(5)","raw_type":"Article"},{"id":"doi:10.17615/w6gf-6j96","doi":"https://doi.org/10.17615/w6gf-6j96","is_oa":true,"landing_page_url":"https://doi.org/10.17615/w6gf-6j96","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.784.2161","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.784.2161","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/01/1d/nihms614700.PMC4480860.pdf","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4480860","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4480860/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Pharmacol Ther","raw_type":"Text"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3230350167","display_name":"Altered Hepatic Disposition of Anionic Drugs-Mechanisms","funder_award_id":"R01GM041935","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"}],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337354","display_name":"National Institute of General Medical Sciences","ror":"https://ror.org/04q48ey07"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2021513482.pdf","grobid_xml":"https://content.openalex.org/works/W2021513482.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W1609658954","https://openalex.org/W1973849443","https://openalex.org/W1976411764","https://openalex.org/W1979820286","https://openalex.org/W1981438405","https://openalex.org/W1984935905","https://openalex.org/W1997264947","https://openalex.org/W1999689787","https://openalex.org/W2001112876","https://openalex.org/W2002532986","https://openalex.org/W2003856834","https://openalex.org/W2008631384","https://openalex.org/W2013209482","https://openalex.org/W2017098775","https://openalex.org/W2021233291","https://openalex.org/W2028992331","https://openalex.org/W2034106555","https://openalex.org/W2035059384","https://openalex.org/W2039569536","https://openalex.org/W2043432548","https://openalex.org/W2045039026","https://openalex.org/W2061542347","https://openalex.org/W2061699782","https://openalex.org/W2065424662","https://openalex.org/W2103616864","https://openalex.org/W2120330455","https://openalex.org/W2122636355","https://openalex.org/W2124260053","https://openalex.org/W2124428389","https://openalex.org/W2133074258","https://openalex.org/W2134837921","https://openalex.org/W2140184005","https://openalex.org/W2142085135","https://openalex.org/W2143810054","https://openalex.org/W2144948193","https://openalex.org/W2148959437","https://openalex.org/W2150286866","https://openalex.org/W2152548885","https://openalex.org/W2156899846","https://openalex.org/W2159029076","https://openalex.org/W2159684898","https://openalex.org/W2165423709","https://openalex.org/W2171636541","https://openalex.org/W2260916829","https://openalex.org/W2302091022","https://openalex.org/W2410048289"],"related_works":["https://openalex.org/W1965554264","https://openalex.org/W2548200758","https://openalex.org/W2955355259","https://openalex.org/W2766589429","https://openalex.org/W3203752138","https://openalex.org/W7015442643","https://openalex.org/W2770940062","https://openalex.org/W2612819896","https://openalex.org/W2302091022"],"abstract_inverted_index":{"Troglitazone":[0],"(TGZ)":[1],"causes":[2],"delayed,":[3],"life-threatening":[4],"drug-induced":[5,157],"liver":[6,45,143,158],"injury":[7,46,159],"in":[8,15,60,63,73,85,110,134,137],"some":[9],"patients":[10],"but":[11],"was":[12,107],"not":[13,99,108],"hepatotoxic":[14,109,168],"rats.":[16],"This":[17],"study":[18],"investigated":[19],"altered":[20],"bile":[21,38,122],"acid":[22,39,123],"homeostasis":[23],"as":[24],"a":[25,31],"mechanism":[26],"of":[27,71,83,87,145,170],"TGZ":[28,53,106,135],"hepatotoxicity":[29],"using":[30],"systems":[32],"pharmacology":[33,148],"model":[34],"incorporating":[35],"drug/metabolite":[36],"disposition,":[37],"physiology/pathophysiology,":[40],"hepatocyte":[41],"life":[42],"cycle,":[43],"and":[44,131,152,161],"biomarkers.":[47],"In":[48,115],"the":[49,68,80,88,111,127,141,167],"simulated":[50,112],"human":[51],"population,":[52],"(200-600":[54],"mg/day":[55,94],"\u00d7":[56,95],"6":[57,96],"months)":[58,97],"resulted":[59],"delayed":[61,129],"increases":[62],"serum":[64],"alanine":[65],"transaminase":[66],">3\u00d7":[67],"upper":[69,81],"limit":[70,82],"normal":[72,84],"0.3-5.1%,":[74],"with":[75,103],"concomitant":[76],"bilirubin":[77],"elevations":[78],">2\u00d7":[79],"0.3-3.6%,":[86],"population.":[89,114],"By":[90],"contrast,":[91],"pioglitazone":[92],"(15-45":[93],"did":[98],"elicit":[100],"hepatotoxicity,":[101,136],"consistent":[102],"clinical":[104],"data.":[105],"rat":[113],"summary,":[116],"mechanistic":[117],"modeling":[118],"based":[119],"only":[120],"on":[121],"effects":[124],"accurately":[125],"predicted":[126],"incidence,":[128],"presentation,":[130],"species":[132],"differences":[133],"addition":[138],"to":[139,165],"predicting":[140],"relative":[142],"safety":[144],"pioglitazone.":[146],"Systems":[147],"models":[149],"integrating":[150],"physiology":[151],"experimental":[153],"data":[154],"can":[155],"evaluate":[156],"mechanisms":[160],"may":[162],"be":[163],"useful":[164],"predict":[166],"potential":[169],"drug":[171],"candidates.":[172]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2021513482","counts_by_year":[{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":19},{"year":2016,"cited_by_count":17},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
